Top Markets
Coin of the day
Nuformix plc Nuformix plc

Nuformix plc

NFX
株式のランク #41013
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes... Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
株価
$0.00185055
時価総額
$48.29K
変化(1日)
-3.55%
変化(1年)
30.31%
GB
取引 Nuformix plc (NFX)

カテゴリー

Nuformix plc(NFX)の収益
Mar 2026 時点の収益 TTM: 0.00
Nuformix plc の最新の財務報告によると、現在の収益 (TTM) は 0.00 です。2024 年には 0.00 の収益があり、これは 2023 年の 0.00 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Nuformix plc の収益履歴(2014 ~ 2026)
各年末の収益
収益 変化
2026 (TTM) 0.00 0.00%
2025 0.00 0.00%
2024 0.00 0.00%
2023 0.00 -100.00%
2022 $65.73K -75.61%
2021 $269.56K -59.39%
2020 $663.79K -16.44%
2019 $794.35K 3,678.32%
2018 $21.02K 0.00%
2017 0.00 -100.00%
2016 $872.91K 181.15%
2014 $310.47K 0.00%
同業他社の収益
企業 収益 収益の差
$12.62B -
US
$2.23B -
US
$15.74B -
AU
$6.02B -
NL
- -
CH